Psyence BioMed to Visit U.S. to Promote Psychedelic Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Psyence BioMed announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives. The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, including ibogaine. The purpose of the Company's upcoming U.S. engagement initiative is to educate and inform stakeholders on the complexity, regulatory considerations, and scientific infrastructure required to manufacture pharmaceutical-grade ibogaine under Good Manufacturing Practice standards suitable for regulated clinical research. "We believe global interest in ibogaine research continues to accelerate, particularly as policymakers, researchers, and healthcare institutions explore innovative approaches to serious mental health conditions," said Jody Aufrichtig, CEO of Psyence BioMed. "Our objective during this visit is to contribute constructively to those conversations by sharing our expertise and helping stakeholders better understand the highly specialized process required to produce compliant pharmaceutical-grade ibogaine suitable for regulated research environments."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Psyence BioMed Advances Psychedelic Research Initiatives in the U.S.
- Executive Visit to the U.S.: Psyence BioMed's executive leadership team plans to visit the U.S. in the coming weeks to engage with researchers and government officials, emphasizing the company's commitment to advancing psychedelic research and policy initiatives.
- Policy Support: This visit follows recent U.S. policy developments aimed at fostering research collaboration and clinical investigations involving psychedelics, indicating the company's strategic positioning in response to regulatory changes.
- GMP-Compliant Production: Psyence BioMed has established GMP-compliant manufacturing capabilities in Southern Africa, enabling the large-scale production of pharmaceutical-grade ibogaine, thereby enhancing its competitive edge within the global psychedelic supply chain.
- Growing Market Demand: With increasing global interest in ibogaine research, Psyence BioMed is actively engaging with U.S.-based research institutions to meet future clinical research demands for compliant manufacturing capabilities, further solidifying its market position.
See More
Pacific Bay Minerals Adopts Semi-Annual Reporting
- Reporting Frequency Change: Pacific Bay Minerals is shifting to semi-annual financial reporting starting with Q1 2026, complying with the British Columbia Securities Commission's Order 51-933, aimed at reducing management costs while enhancing transparency.
- Exploration Project Reactivation: This move allows the company to focus more resources on reactivating the Haskin-Reed critical minerals project, which is expected to drive future mineral development and potential revenue.
- Significant Project Potential: The Haskin-Reed project, located in the Cassiar Region, hosts rich deposits of tungsten, copper, bismuth, silver, lead, and zinc across over 150 drill holes, indicating substantial exploration potential.
- Acquisition Agreement Signed: The company recently signed an option agreement to acquire the Mount Haskins claims, directly enhancing its resource base in the area, which is anticipated to support future mining activities.
See More
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Policy Catalyst: Trump's executive order directs the FDA to expedite the review of psychedelic drugs and commits $50 million to related clinical research, which is expected to significantly enhance market recognition and attract investment in psychedelic therapies.
- Inventory Advantage: Psyence Biomedical currently holds standardized, stabilized GMP-compliant ibogaine doses, addressing the scarcity of clinical-grade materials in the market, which is likely to strengthen its competitive position in the psychedelic drug sector.
- Vertical Integration: Through its investment in PsyLabs, Psyence has established a vertically integrated platform that spans sourcing in Africa, extraction, purification, and pharmaceutical production, effectively reducing supply chain delays and accelerating progress in ibogaine-based clinical research.
- Surging Market Sentiment: PBM shares surged 182% over the past three days, with retail sentiment on Stocktwits being extremely bullish, indicating strong market confidence in the company's future, which may attract more investors to the psychedelic drug market.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Trump Accelerates Psychedelic Research, PBM Stock Soars
- Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
- Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
- Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
- Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
See More
Psyence BioMed Advances Psychedelic Research Initiatives in the U.S.
- Executive Visit to the U.S.: Psyence BioMed's executive leadership team plans to visit the U.S. in the coming weeks to engage with researchers and government officials, emphasizing the company's commitment to advancing psychedelic research and policy initiatives.
- Policy Support: This visit follows recent U.S. policy developments aimed at fostering research collaboration and clinical investigations involving psychedelics, indicating the company's strategic positioning in response to regulatory changes.
- GMP-Compliant Production: Psyence BioMed has established GMP-compliant manufacturing capabilities in Southern Africa, enabling the large-scale production of pharmaceutical-grade ibogaine, thereby enhancing its competitive edge within the global psychedelic supply chain.
- Growing Market Demand: With increasing global interest in ibogaine research, Psyence BioMed is actively engaging with U.S.-based research institutions to meet future clinical research demands for compliant manufacturing capabilities, further solidifying its market position.
See More
Pacific Bay Minerals Adopts Semi-Annual Reporting
- Reporting Frequency Change: Pacific Bay Minerals is shifting to semi-annual financial reporting starting with Q1 2026, complying with the British Columbia Securities Commission's Order 51-933, aimed at reducing management costs while enhancing transparency.
- Exploration Project Reactivation: This move allows the company to focus more resources on reactivating the Haskin-Reed critical minerals project, which is expected to drive future mineral development and potential revenue.
- Significant Project Potential: The Haskin-Reed project, located in the Cassiar Region, hosts rich deposits of tungsten, copper, bismuth, silver, lead, and zinc across over 150 drill holes, indicating substantial exploration potential.
- Acquisition Agreement Signed: The company recently signed an option agreement to acquire the Mount Haskins claims, directly enhancing its resource base in the area, which is anticipated to support future mining activities.
See More
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Policy Catalyst: Trump's executive order directs the FDA to expedite the review of psychedelic drugs and commits $50 million to related clinical research, which is expected to significantly enhance market recognition and attract investment in psychedelic therapies.
- Inventory Advantage: Psyence Biomedical currently holds standardized, stabilized GMP-compliant ibogaine doses, addressing the scarcity of clinical-grade materials in the market, which is likely to strengthen its competitive position in the psychedelic drug sector.
- Vertical Integration: Through its investment in PsyLabs, Psyence has established a vertically integrated platform that spans sourcing in Africa, extraction, purification, and pharmaceutical production, effectively reducing supply chain delays and accelerating progress in ibogaine-based clinical research.
- Surging Market Sentiment: PBM shares surged 182% over the past three days, with retail sentiment on Stocktwits being extremely bullish, indicating strong market confidence in the company's future, which may attract more investors to the psychedelic drug market.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Trump Accelerates Psychedelic Research, PBM Stock Soars
- Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
- Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
- Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
- Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
See More
